Allergy Therapeutics (LON:AGY) Reaches New 1-Year Low – Here’s Why

by · The Markets Daily

Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as GBX 6.50 and last traded at GBX 7.50, with a volume of 203060 shares changing hands. The stock had previously closed at GBX 7.50.

Allergy Therapeutics Stock Up 0.3%

The firm has a market cap of £474.94 million, a PE ratio of -7.73, a PEG ratio of -30.70 and a beta of 0.89. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The firm has a 50 day moving average price of GBX 9.63 and a 200-day moving average price of GBX 10.53.

Allergy Therapeutics (LON:AGY – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported GBX (0.38) earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 85.46% and a positive return on equity of 409.00%. The firm had revenue of GBX 3,628 million during the quarter. Research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current fiscal year.

Allergy Therapeutics Company Profile

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

Featured Articles